NeonMind Biosciences Inc. (OTCQB:NMDBF) (CSE:NEON) (FRA:6UF) has filed a new patent application with the U.S. Patent and Trademark Office related to a novel mechanism of weight loss targeted to specific fat subtypes.
The provisional patent application includes data derived from NeonMind's recent preclinical animal study, incorporating novel findings which indicate, in addition to reiterating weight modulation effects of psilocybin seen in previous studies, that the targeted reduction of specific fat subtypes may have beneficial effects on metabolic and cardiovascular health.
The filing strengthens NeonMind's growing IP portfolio and differentiates the commercial profiles of its drug candidates. The company plans to release further details of the study's findings.
If granted, the patent could support NeonMind's pharmaceutical assets until at least 2042. NeonMind's lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind's additional drug candidate, NEO-002, employs low-dose psilocybin to control appetite.
"We are excited by the unique findings from our preclinical studies, which have demonstrated durable therapeutic benefits for weight management in the animal model. Importantly, our novel findings provide an opportunity for us to develop drugs with highly differentiated target product profiles and broad commercial opportunities," stated Robert Tessarolo, president & CEO of NeonMind.
"With the advancement of our research programs and continued expansion of our IP portfolio, NeonMind is positioning itself as a leading innovator in the development of novel psychedelic treatments focused on serving the weight management and obesity market, which has historically been underserved and where a new, effective approach is desperately needed to help people live fuller, healthier lives," concluded Tessarolo.
To hear more about the important and fascinating scientific advances and meet face-to-face with some of this nascent industry’s professionals & market leaders, join us at the Benzinga Psychedelics Capital Conference on April 19, 2022 at the Fontainebleau Miami Beach where we are bringing together leaders of the largest publicly-traded Psychedelics companies with investors from across North America.
Tickets for this first-of-its-kind gathering are still available here.
Photo: Courtesy of Marco Allegretti on Unsplash
